No abstract

The review analyzes the latest American clinical guidelines on the effectiveness of cervical cancer screening programs, as well as references on the use of the immunomodulator isoprinosine for the treatment of patients infected with the human papilloma virus (HPV). The high prevalence of HPV and its role in the development of cervical cancer are shown. Isoprinosine belongs to immunomodulators with antiviral activity. It inhibits the replication of viral DNA and RNA by binding to cell ribosomes and changing their stereochemical structure. HPV infection, especially in the early stages, may be successfully cured till the complete elimination of the virus. Inosine Pranobex (Izoprinozin) having dual action and the most abundant evidence base, may be recognized as the optimal treatment option.

HIGHLIGHTS Endometriosis treatment is still a challenge for modern medicine Therapy with combined oral contraceptives (COCs) may be reconsidered at least for some patients Progestogens may be an effective alternative to COCs when it comes to endometriosis-related pelvic pain Aim The aim of this review article was to analyze and summarize the current treatment options of endometriosis-associated pain to provide additional information about treatment personalization for clinicians. Background Despite numerous studies being published, endometriosis is still one of the main challenges in gynecology. The etiology of endometriosis is unclear while its mechanism is believed to be connected to the peritoneal endometriotic lesions via retrograde menstruation, immunity abnormalities, and genetic, environmental, and lifestyle factors. Patients with endometriosis generally have to cope with chronic pelvic pain which definitely affects the quality of life. The disease is often characterized by a persistent recurrent course; therefore, when choosing a treatment, special attention should be paid not only to its efficacy, but also to long-term safety, tolerability, and compliance. Review results Actual and relevant publications in PubMed and eLibrary databases were studied. The authors highlight the pathogenic mechanisms of endometriosis and the current state of pharmacological management options. The available evidence on the use of combined oral contraceptives (COCs) for pelvic pain is critically assessed and the authors propose their opinion on the alternative treatment options with progestogens which seem to be an effective alternative to COCs with a more favorable safety profile. Conclusion Progestogens are an effective alternative to COCs in the treatment of endometriosis-associated pain; however, further well-conducted trials are needed in both types of therapy. Clinical significance The results of this literature review provide additional information to enable clinicians to personalize the treatment of endometriosis-associated pain. How to cite this article Dubrovina SO, Berlim YD, Bezhenar VF, et al. Pharmacological Management of Endometriosis-related Pain: The Expert Opinion. J South Asian Feder Obst Gynae 2020;12(6):415–420.

No abstract